What is Caidya?
Caidya operates as a sophisticated clinical research organization (CRO) that provides comprehensive support to innovators across the entire drug development lifecycle. From pre-IND strategy and clinical trial execution to post-marketing surveillance, the company distinguishes itself through a focus on delivery excellence and an elevated customer experience. By integrating proprietary clinical technology, Caidya ensures trial transparency and facilitates informed, data-driven decision-making for its global partners. The firm's multi-therapeutic expertise allows it to navigate complex regulatory environments, effectively bridging the gap between early-stage research and commercial submission.
How much funding has Caidya raised?
Caidya has raised a total of $297.8M across 14 funding rounds:
Debt
$13M
Debt
$3M
Debt
$4M
Private Equity
$50M
Private Equity
$3.7M
Debt
$3M
Private Equity
$10M
Debt
$18.4M
Debt
$2M
Other Financing Round
$165M
Debt (2012): $13M, investors not publicly disclosed
Debt (2014): $3M with participation from Undisclosed
Debt (2014): $4M, investors not publicly disclosed
Private Equity (2015): $50M supported by Hatteras Venture Partners, Crestline Investors, Inc., and Virgo Investment Group, LLC
Private Equity (2016): $3.7M, investors not publicly disclosed
Debt (2017): $3M backed by Undisclosed
Private Equity (2017): $10M, investors not publicly disclosed
Debt (2020): $18.4M, investors not publicly disclosed
Debt (2020): $2M supported by PPP
Other Financing Round (2025): $165M featuring Rubicon Founders
Key Investors in Caidya
Rubicon Founders
Rubicon Founders is an entrepreneurial healthcare investment firm dedicated to building and growing transformational companies that deliver enduring value in healthcare delivery.
Hatteras Venture Partners
A venture capital firm specializing in early-stage life sciences and healthcare investments, focusing on companies with the potential to improve human health.
Crestline Investors, Inc.
An institutional investment management firm that provides flexible capital solutions and strategic support to companies across various sectors, including healthcare.
What's next for Caidya?
With the recent injection of capital, Caidya is poised to scale its technological infrastructure and enhance its service delivery model. The strategic focus will likely center on deepening its therapeutic reach and optimizing trial efficiency through advanced digital tools. As the CRO landscape continues to consolidate, Caidya's ability to maintain high-touch service while scaling operations will be critical. Investors and industry stakeholders will be monitoring how the firm utilizes this latest financing to drive innovation in clinical trial management and maintain its competitive edge in a rapidly evolving healthcare market.
See full Caidya company page
